US · BBLGW
Bone Biologics Corporation
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Burlington, MA 01803
- Website
- bonebiologics.com
Price · as of 2024-12-31
—
Market cap 4.18M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | — | — |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | |||||
| 2020 | |||||
| 2021 | $0.23 | ||||
| 2022 | $0.06 | ||||
| 2023 | $19.58 | ||||
| 2024 | $20.20 |
AI valuation
Our deep-learning model estimates Bone Biologics Corporation's (BBLGW) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- —
- Current price
- —
- AI upside
- —
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| BBLGW | Bone Biologics Corporatio… | $12.00 | 4.18M | — | — | — | — | -7.45 | 8.80 | — | -6.64 | — | 8.80 | 0.00% | — | — | -128.71% | -22020.98% | -108.23% | 0.00 | — | 10.22 | 8.80 | 0.81 | -8580.00% | — | -5683.00% | -13.46% | -10.92 | -21530.04% | 10.48% | -78.10% | 11.46% | -6.48 | -6.62 | — | 15.33 |
| AMIX | Autonomix Medical, Inc. C… | $0.84 | 4.3M | — | — | — | — | -0.23 | 0.32 | — | 0.59 | — | 0.32 | 0.00% | — | — | -145.10% | 2283.35% | -118.77% | 0.00 | -65.84 | 5.63 | 5.35 | 0.83 | -6937.00% | — | 2407.00% | -316.49% | -4.84 | 1629.95% | 0.00% | 0.00% | 58.54% | 0.56 | 0.79 | — | -9.21 |
| BGMS | Bio Green Med Solution, I… | $1.65 | 3.69M | +1,306,220% | +2,232,759% | — | +2,368,039% | -0.07 | -0.38 | 19.24 | 0.19 | — | -0.38 | 100.00% | -27916.28% | -26074.42% | 1431.01% | 278.96% | -173.84% | 0.00 | — | 0.59 | 0.54 | 0.26 | -9219.00% | -8976.00% | -5043.00% | -965.78% | -1.27 | 198.63% | 0.00% | 0.00% | 0.00% | 0.19 | 0.29 | -53.71 | -160.64 |
| CNSP | CNS Pharmaceuticals, Inc. | $6.82 | 3.92M | — | — | — | — | -0.68 | 1.63 | — | -0.27 | — | 1.63 | 0.00% | — | — | -1703.39% | 642.50% | -285.68% | 0.05 | -924.50 | 3.43 | 2.91 | 0.41 | -3522.00% | — | 2102.00% | -169.67% | -6.78 | 738.03% | 0.00% | 0.00% | 58.36% | -0.27 | -0.23 | — | -15.99 |
| DHAI | DIH Holding US, Inc. | $1.82 | 3.81M | +1,508% | +20% | — | — | -903.76 | -211.15 | 124.73 | -1104.70 | — | -211.15 | 51.24% | -7.74% | -13.80% | 24.90% | 20.72% | -27.77% | -0.32 | -15.34 | 0.49 | 0.12 | -1.41 | -2412.00% | -250.00% | -19379.00% | -0.06% | -0.10 | 19.94% | 0.00% | 0.00% | 0.03% | -1614.12 | -1677.58 | 124.89 | 72.12 |
| HSCS | HeartSciences Inc. | $2.90 | 6.52M | +667% | -43% | — | +20,854% | -0.45 | 19.02 | 897.28 | -0.71 | — | -2.77 | -2884.71% | -192013.13% | -201499.52% | -233.04% | -360.16% | -127.72% | 14.55 | -16.69 | 0.59 | 0.30 | -0.23 | -5016.00% | -7661.00% | 2014.00% | -190.70% | -2.00 | -320.95% | 0.00% | 0.00% | 0.00% | -0.69 | -0.78 | 1331.10 | -31.62 |
| MOVE | Movano Inc. | $5.30 | 3.79M | — | — | — | — | -90.32 | 291.38 | 2115.60 | -88.77 | — | 291.38 | -196.84% | -2391.12% | -2342.25% | -439.23% | 1722.15% | -228.79% | 0.03 | — | 3.02 | 2.31 | 0.32 | -3810.00% | — | -1410.00% | -1.05% | -6.54 | 1602.63% | 0.00% | 0.00% | 0.08% | -88.16 | -94.73 | 2107.98 | 299.75 |
| NAOV | NanoVibronix, Inc. | $4.84 | 3.86M | +29,176% | +225% | — | — | -2.87 | 16.95 | 4.15 | -2.71 | — | 16.95 | 58.95% | -140.03% | -144.84% | -160.56% | -1021.97% | -71.92% | 0.19 | -26.53 | 1.22 | 0.37 | 0.17 | -3524.00% | 1205.00% | -3009.00% | -23.70% | -0.92 | -718.69% | 0.00% | 0.00% | 0.00% | -2.79 | -3.97 | 3.91 | -27.16 |
| RDHL | RedHill Biopharma Ltd. | $1.11 | 3.7M | +35,030% | +14% | — | — | -0.94 | -1.66 | 0.97 | -0.46 | — | -0.76 | 60.31% | -181.69% | -102.80% | 632.60% | 242.32% | -40.24% | -0.08 | -265.69 | 0.54 | 0.37 | 0.56 | -11522.00% | 2317.00% | -7383.00% | -120.72% | -0.42 | 155.51% | 0.00% | 0.00% | 0.00% | -0.24 | -0.37 | 0.44 | -34.89 |
| SILO | Silo Pharma, Inc. | $0.51 | 4.03M | +3,652% | +34% | — | — | -1.09 | 0.95 | 66.36 | 0.52 | — | 1.00 | 91.90% | -6526.44% | -6092.59% | -78.37% | 266.27% | -57.96% | 0.00 | -925.59 | 4.29 | 4.28 | 0.89 | -83.00% | 0.00% | 1890.00% | -80.13% | -2.32 | 216.94% | 0.00% | 0.00% | 11.59% | 0.49 | 0.60 | -31.84 | -2.88 |
| VERO | Venus Concept Inc. | $2.11 | 3.92M | +5,399% | -43% | — | +19,432% | -0.05 | 0.91 | 0.03 | -1.14 | -0.01 | -0.83 | 68.34% | -41.93% | -72.49% | 806.37% | -52.93% | -58.05% | 18.16 | -3.55 | 1.60 | 0.78 | -1.08 | 86901.00% | -1509.00% | -1376.00% | -520.15% | -0.37 | -22.07% | 0.00% | 0.00% | 1652.41% | -1.50 | -3.66 | 0.63 | -6.37 |
About Bone Biologics Corporation
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. Its NELL-1/DBX is a combination product, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The company is developing NELL-1/DBX Fusion Device for spinal fusion procedures in skeletally mature patients with degenerative disc disease at one level from L4-S1. Its platform technology has application in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
- CEO
- Jeffrey Frelick
- Employees
- 2
- Beta
- 0.51
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ —) − 1 = — (DCF, example).